ArticlePostepy w kardiologii interwencyjnej = Advances in interventional cardiology2025
Serotonin as a potential marker of endothelial dysfunction for cerebral embolism in patients with persistent foramen ovale.
Article in Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A persistent patent foramen ovale (PFO) is a congenital heart defect that predisposes to crossed embolism resulting in stroke. The defect can be accompanied by endothelial dysfunction. One marker reflecting endothelial dysfunction is serotonin, the concentration of which can be increased by passing through the PFO, thus bypassing degradation in the lungs. Aim: To study the potential association between endothelial dysfunction and the occurrence of cryptogenic stroke in patients with PFO, compared with patients without PFO and without a history of cryptogenic stroke. Material and methods: Seventy-nine patients were recruited, including 51 (64.65%) women and 28 (35.44%) men, who underwent PFO closure surgery within the Clinical Department of Cardiovascular Diseases of the John Paul II Specialized Hospital of Krakow, Poland, for a history of cryptogenic stroke between 2009 and 2021. The mean age was 48.34 ±13.13 years. The control group consisted of 79 patients (male and female) without a stroke history. Patients underwent the following examinations: subject and physical examination, transthoracic and transesophageal echocardiography, and laboratory tests including serotonin levels collected before the PFO closure procedure. Results: There was a statistically significant difference between serotonin levels in the study group and the control group (1645.55 ±801.26 vs. 856.98 ±781.63; Conclusions: Serotonin levels appear to be significantly higher in patients with PFO after cryptogenic stroke compared with patients without PFO and stroke history. The length and width of the PFO canal may not correlate with serotonin levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.